Filtered By:
Source: Circulation
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 925 results found since Jan 2013.
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
CONCLUSIONS: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment.REGISTRATION: URL: http://www.CLINICALTRIALS: gov; Unique identifier: NCT02961348.PMID:36065821 | DOI:10.1161/CIRCULATIONAHA.122.060666
Source: Circulation - September 6, 2022 Category: Cardiology Authors: Jonas Oldgren Signild Åsberg Ziad Hijazi Per Wester Maria Bertilsson Bo Norrving National TIMING Collaborators Source Type: research
Correction to: Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association
Circulation. 2022 Sep 6;146(10):e141. doi: 10.1161/CIR.0000000000001074. Epub 2022 Sep 6.NO ABSTRACTPMID:36067280 | DOI:10.1161/CIR.0000000000001074
Source: Circulation - September 6, 2022 Category: Cardiology Source Type: research
Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
CONCLUSIONS: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment.REGISTRATION: URL: http://www.CLINICALTRIALS: gov; Unique identifier: NCT02961348.PMID:36065821 | DOI:10.1161/CIRCULATIONAHA.122.060666
Source: Circulation - September 6, 2022 Category: Cardiology Authors: Jonas Oldgren Signild Åsberg Ziad Hijazi Per Wester Maria Bertilsson Bo Norrving National TIMING Collaborators Source Type: research
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
State of the Science: The Relevance of Symptoms in Cardiovascular Disease and Research: A Scientific Statement From the American Heart Association
Circulation. 2022 Aug 18:101161CIR0000000000001089. doi: 10.1161/CIR.0000000000001089. Online ahead of print.ABSTRACTSymptoms of cardiovascular disease drive health care use and are a major contributor to quality of life. Symptoms are of fundamental significance not only to the diagnosis of cardiovascular disease and appraisal of response to medical therapy but also directly to patients' daily lives. The primary purpose of this scientific statement is to present the state of the science and relevance of symptoms associated with cardiovascular disease. Symptoms as patient-reported outcomes are reviewed in terms of the genes...
Source: Circulation - August 18, 2022 Category: Cardiology Authors: Corrine Y Jurgens Christopher S Lee Dawn M Aycock Ruth Masterson Creber Quin E Denfeld Holli A DeVon Linda R Evers Miyeon Jung Gianluca Pucciarelli Megan M Streur Marvin A Konstam American Heart Association Council on Cardiovascular and Stroke Nursing; Co Source Type: research
Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden
CONCLUSIONS: Patients with recently diagnosed atrial fibrillation and CHA2DS2-VASc score ≥4 should be considered for ERC to reduce cardiovascular outcomes, whereas those with fewer comorbidities may have less favorable outcomes with ERC.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01288352; URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20; URL: https://www.isrctn.com/; Unique identifier: ISRCTN04708680.PMID:35968706 | DOI:10.1161/CIRCULATIONAHA.122.060274
Source: Circulation - August 15, 2022 Category: Cardiology Authors: Andreas Rillig Katrin Borof G ünter Breithardt A John Camm Harry J G M Crijns Andreas Goette Karl-Heinz Kuck Andreas Metzner Panos Vardas Eik Vettorazzi Karl Wegscheider Antonia Zapf Paulus Kirchhof Source Type: research
Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction
CONCLUSIONS: Patients with HFpEF in whom LVEF ranged from 50% to 60% demonstrated reduced contractility, impaired ventriculo-arterial coupling, and higher extracellular volume fraction. In contrast, patients with HFpEF and a LVEF >60% demonstrated a hypercontractile state with excessive LV afterload and diminished preload reserve. A LVEF-based stratification of patients with HFpEF identified distinct morphologic and pathophysiologic subphenotypes.PMID:35862208 | DOI:10.1161/CIRCULATIONAHA.122.059280
Source: Circulation - July 21, 2022 Category: Cardiology Authors: Sebastian Rosch Karl-Patrik Kresoja Christian Besler Karl Fengler Anne Rebecca Sch öber Maximilian von Roeder Christian L ücke Matthias Gutberlet Karin Klingel Holger Thiele Karl-Philipp Rommel Philipp Lurz Source Type: research
Nurse Navigators Cut Stroke Readmissions by Half
Circulation. 2022 Jul 12;146(2):140-141. doi: 10.1161/CIRCULATIONAHA.122.060419. Epub 2022 Jul 11.NO ABSTRACTPMID:35858160 | DOI:10.1161/CIRCULATIONAHA.122.060419
Source: Circulation - July 20, 2022 Category: Cardiology Authors: Bridget M Kuehn Source Type: research
